BG105218A - The use of optically pure (+) norcisapride for treating gastro-esophageal reflux disease - Google Patents
The use of optically pure (+) norcisapride for treating gastro-esophageal reflux diseaseInfo
- Publication number
- BG105218A BG105218A BG105218A BG10521801A BG105218A BG 105218 A BG105218 A BG 105218A BG 105218 A BG105218 A BG 105218A BG 10521801 A BG10521801 A BG 10521801A BG 105218 A BG105218 A BG 105218A
- Authority
- BG
- Bulgaria
- Prior art keywords
- norcisapride
- compound
- optically pure
- reflux disease
- esophageal reflux
- Prior art date
Links
- ZDLILMQNLSEPLK-UHFFFAOYSA-N 2-chloro-5-methoxy-n-piperidin-4-ylpyrimidin-4-amine Chemical compound COC1=CN=C(Cl)N=C1NC1CCNCC1 ZDLILMQNLSEPLK-UHFFFAOYSA-N 0.000 title abstract 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000002411 adverse Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- OMLDMGPCWMBPAN-YPMHNXCESA-N norcisapride Chemical compound CO[C@H]1CNCC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC OMLDMGPCWMBPAN-YPMHNXCESA-N 0.000 abstract 2
- 230000003389 potentiating effect Effects 0.000 abstract 2
- 206010013710 Drug interaction Diseases 0.000 abstract 1
- 206010052105 Gastrointestinal hypomotility Diseases 0.000 abstract 1
- 206010021518 Impaired gastric emptying Diseases 0.000 abstract 1
- 201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 abstract 1
- 239000002111 antiemetic agent Substances 0.000 abstract 1
- 229940125683 antiemetic agent Drugs 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 201000006549 dyspepsia Diseases 0.000 abstract 1
- 230000005176 gastrointestinal motility Effects 0.000 abstract 1
- 208000001288 gastroparesis Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/123,892 US6147093A (en) | 1996-07-19 | 1998-07-28 | Methods for treating gastroesophageal reflux disease |
| PCT/US1999/016736 WO2000006165A1 (en) | 1998-07-28 | 1999-07-23 | Methods and compositions for treating gastro-esophageal reflux disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG105218A true BG105218A (en) | 2001-11-30 |
Family
ID=22411520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG105218A BG105218A (en) | 1998-07-28 | 2001-02-05 | The use of optically pure (+) norcisapride for treating gastro-esophageal reflux disease |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US6147093A (cs) |
| EP (1) | EP1100502A1 (cs) |
| JP (1) | JP2002521448A (cs) |
| KR (1) | KR20010071047A (cs) |
| CN (1) | CN1320036A (cs) |
| AR (1) | AR019947A1 (cs) |
| AU (1) | AU5126099A (cs) |
| BG (1) | BG105218A (cs) |
| BR (1) | BR9912581A (cs) |
| CA (1) | CA2338465A1 (cs) |
| CO (1) | CO5060499A1 (cs) |
| CZ (1) | CZ295776B6 (cs) |
| EA (1) | EA200100188A1 (cs) |
| EE (1) | EE200100051A (cs) |
| HK (1) | HK1041226A1 (cs) |
| HR (1) | HRP20010075A2 (cs) |
| HU (1) | HUP0102979A3 (cs) |
| ID (1) | ID28894A (cs) |
| IL (1) | IL141047A0 (cs) |
| NO (1) | NO20010464L (cs) |
| NZ (1) | NZ509671A (cs) |
| PL (1) | PL345764A1 (cs) |
| SK (1) | SK1202001A3 (cs) |
| TR (1) | TR200100921T2 (cs) |
| WO (1) | WO2000006165A1 (cs) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6147093A (en) * | 1996-07-19 | 2000-11-14 | Sepracor Inc. | Methods for treating gastroesophageal reflux disease |
| DE69818678T2 (de) * | 1997-07-11 | 2004-07-15 | Janssen Pharmaceutica N.V. | (+)-norcisapride verwendbar bei 5-ht3 und 5-ht4 bedingten krankheiten |
| US6353005B1 (en) * | 1999-03-02 | 2002-03-05 | Sepracor, Inc. | Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist |
| DE10314916A1 (de) | 2003-04-01 | 2004-10-21 | Endress + Hauser Flowtec Ag, Reinach | Vorrichtung zur Bestimmung und/oder Überwachung des Volumen- und/oder Massenstroms eines Mediums |
| AU2004303722B2 (en) * | 2003-12-23 | 2010-02-18 | Serodus As | Modulators of peripheral 5-HT receptors |
| US8524736B2 (en) | 2004-01-07 | 2013-09-03 | Armetheon, Inc. | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| US8138204B2 (en) * | 2004-01-07 | 2012-03-20 | Aryx Therapeutics, Inc. | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| BRPI0506736B1 (pt) | 2004-01-07 | 2018-08-21 | Renexxion Llc | Compostos estereoisoéricos para o tratamento de distúrbios gastrointestinais e no sistema nervoso central, e composições |
| US20050160544A1 (en) * | 2004-01-26 | 2005-07-28 | Marc Geller | Contoured grill brush |
| ES2436100T3 (es) * | 2005-08-31 | 2013-12-27 | Armetheon, Inc. | Métodos sintéticos y productos intermedios para compuestos estereoisoméricos útiles para el tratamiento de trastornos del sistema nervioso central y gastrointestinal |
| US20080085915A1 (en) * | 2006-06-23 | 2008-04-10 | Cyrus Becker | Compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| US10570127B1 (en) | 2018-11-05 | 2020-02-25 | Renexxion, Llc | Material and methods for the treatment of gastro-intestinal disorders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057525A (en) * | 1981-10-01 | 1991-10-15 | Janssen Pharmaceutica N.V. | Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives |
| US5137896A (en) * | 1981-10-01 | 1992-08-11 | Janssen Pharmaceutica N.V. | N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
| US4962115A (en) * | 1981-10-01 | 1990-10-09 | Janssen Pharmaceutica N.V. | Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
| JPH08502032A (ja) * | 1992-07-07 | 1996-03-05 | セプラコア インコーポレーテッド | 胃食道逆流疾患およびその他の障害を治療するために▲（−）▼シサプリドを使用する方法 |
| EP0651639A4 (en) * | 1992-07-07 | 1996-06-26 | Sepracor Inc | METHODS OF USING CISAPRIDE (+) FOR THE TREATMENT OF GASTROSOPHAGIC REFLUX AND OTHER DISORDERS. |
| CA2166730A1 (en) * | 1993-07-06 | 1995-01-19 | Robert T. Sims | H2 antagonist-gastrointestinal motility agent combinations |
| US5712293A (en) * | 1995-06-07 | 1998-01-27 | Sepracor, Inc. | Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride |
| US5739151A (en) * | 1996-07-19 | 1998-04-14 | Sepracor Inc. | Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride |
| US6147093A (en) * | 1996-07-19 | 2000-11-14 | Sepracor Inc. | Methods for treating gastroesophageal reflux disease |
| DE69818678T2 (de) * | 1997-07-11 | 2004-07-15 | Janssen Pharmaceutica N.V. | (+)-norcisapride verwendbar bei 5-ht3 und 5-ht4 bedingten krankheiten |
-
1998
- 1998-07-28 US US09/123,892 patent/US6147093A/en not_active Expired - Fee Related
-
1999
- 1999-07-23 NZ NZ509671A patent/NZ509671A/en unknown
- 1999-07-23 EE EEP200100051A patent/EE200100051A/xx unknown
- 1999-07-23 PL PL99345764A patent/PL345764A1/xx not_active Application Discontinuation
- 1999-07-23 CN CN99811374A patent/CN1320036A/zh active Pending
- 1999-07-23 KR KR1020017001188A patent/KR20010071047A/ko not_active Ceased
- 1999-07-23 JP JP2000562019A patent/JP2002521448A/ja active Pending
- 1999-07-23 WO PCT/US1999/016736 patent/WO2000006165A1/en active IP Right Grant
- 1999-07-23 HU HU0102979A patent/HUP0102979A3/hu unknown
- 1999-07-23 AU AU51260/99A patent/AU5126099A/en not_active Abandoned
- 1999-07-23 ID IDW20010484A patent/ID28894A/id unknown
- 1999-07-23 HK HK02103109.0A patent/HK1041226A1/zh unknown
- 1999-07-23 IL IL14104799A patent/IL141047A0/xx unknown
- 1999-07-23 EP EP99935877A patent/EP1100502A1/en not_active Withdrawn
- 1999-07-23 BR BR9912581-1A patent/BR9912581A/pt not_active Application Discontinuation
- 1999-07-23 HR HR20010075A patent/HRP20010075A2/hr not_active Application Discontinuation
- 1999-07-23 CZ CZ2001348A patent/CZ295776B6/cs not_active IP Right Cessation
- 1999-07-23 SK SK120-2001A patent/SK1202001A3/sk unknown
- 1999-07-23 TR TR2001/00921T patent/TR200100921T2/xx unknown
- 1999-07-23 CA CA002338465A patent/CA2338465A1/en not_active Abandoned
- 1999-07-23 EA EA200100188A patent/EA200100188A1/ru unknown
- 1999-07-28 AR ARP990103729A patent/AR019947A1/es not_active Application Discontinuation
- 1999-07-28 CO CO99047624A patent/CO5060499A1/es unknown
-
2000
- 2000-05-18 US US09/573,423 patent/US6242465B1/en not_active Expired - Fee Related
-
2001
- 2001-01-26 NO NO20010464A patent/NO20010464L/no not_active Application Discontinuation
- 2001-02-05 BG BG105218A patent/BG105218A/xx unknown
- 2001-03-16 US US09/809,165 patent/US6632827B2/en not_active Expired - Fee Related
-
2003
- 2003-09-03 US US10/653,072 patent/US20040044039A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1320036A (zh) | 2001-10-31 |
| BR9912581A (pt) | 2001-05-02 |
| NO20010464D0 (no) | 2001-01-26 |
| HK1041226A1 (zh) | 2002-07-05 |
| CA2338465A1 (en) | 2000-02-10 |
| US20040044039A1 (en) | 2004-03-04 |
| EA200100188A1 (ru) | 2001-08-27 |
| US20010020031A1 (en) | 2001-09-06 |
| IL141047A0 (en) | 2002-02-10 |
| CZ295776B6 (cs) | 2005-11-16 |
| AR019947A1 (es) | 2002-03-27 |
| TR200100921T2 (tr) | 2001-10-22 |
| PL345764A1 (en) | 2002-01-02 |
| EE200100051A (et) | 2002-06-17 |
| CO5060499A1 (es) | 2001-07-30 |
| US6632827B2 (en) | 2003-10-14 |
| HUP0102979A3 (en) | 2002-01-28 |
| ID28894A (id) | 2001-07-12 |
| CZ2001348A3 (cs) | 2002-01-16 |
| JP2002521448A (ja) | 2002-07-16 |
| US6242465B1 (en) | 2001-06-05 |
| AU5126099A (en) | 2000-02-21 |
| SK1202001A3 (en) | 2001-08-06 |
| EP1100502A1 (en) | 2001-05-23 |
| NO20010464L (no) | 2001-03-23 |
| US6147093A (en) | 2000-11-14 |
| KR20010071047A (ko) | 2001-07-28 |
| HRP20010075A2 (en) | 2002-02-28 |
| NZ509671A (en) | 2003-08-29 |
| WO2000006165A1 (en) | 2000-02-10 |
| HUP0102979A2 (hu) | 2001-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2245768A1 (en) | Methods for treating emesis and central nervous system disorders using optically pure (+) norcisapride | |
| BG105218A (en) | The use of optically pure (+) norcisapride for treating gastro-esophageal reflux disease | |
| PT1259489E (pt) | Compostos azapoliciclicos condensados con arilo. | |
| AU6926800A (en) | Bupropion metabolites and methods of their synthesis and use | |
| DE60140693D1 (en) | Ankheiten | |
| CA2272584A1 (en) | Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases | |
| MY111616A (en) | Nover (r)-5-carbamoyl-8-fluoro-3-n, n-disubstituted-amino-3, 4-dihydro-2h-1-benzopyrans | |
| UA87653C2 (en) | 1,2,4-oxadiazols as modulators of receptor-5 for metabotropic glutamate | |
| PL370373A1 (en) | Substituted piperidines as modulators of the melanocortin receptor | |
| EG20218A (en) | Process for preparing of substituted 3 aminoquinuclidines | |
| EP1165086A4 (en) | BUPROPION METABOLITES AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
| WO2003020212A3 (en) | Treatment for central nervous system disorders | |
| MXPA02008770A (es) | Compuestos azaciclicos para uso en el tratamiento de enfermedades relacionadas con la serotonina. | |
| HK1049333A1 (zh) | 以环状琥珀酸酯代替内酰胺，作为制造Aβ蛋白质的抑制剂 | |
| GEP20043366B (en) | Benzothiophene Derivative Compounds Process of Preparation and Use Thereof | |
| MY140835A (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
| CA2242879A1 (en) | Method for treating sexual dysfunctions | |
| MXPA04004368A (es) | Metodos para tratar depresion y otros transtornos del sistema nervioso central utilizando desmetil-y didesmetil-metabolitos del citalopram enantiomericamente enriquecidos. | |
| BG103949A (en) | A new salt | |
| FR2724933B1 (cs) | ||
| BG103512A (en) | Substituted pyramidine compounds and their application | |
| IL136030A0 (en) | Propylisopropyl acetic acid and propylisopropyl acetamide racemic mixtures, a method for their synthesis and pharmaceutical compositions containing them | |
| BG101929A (en) | Benzamides for neurodegenerative disorder treatment | |
| CA2123704A1 (en) | Methods and compositions utilizing pure s(+)isomer fluoxetine | |
| GB0019008D0 (en) | Therapeutic compounds |